Biotech Co.* |
Pharma Co. (Country) | Product |
Terms/Details (Date) |
| | |||
Adolor Corp. |
GlaxoSmithKline plc (UK) |
Adolor will co-promote GSK's anti-thrombotic agent Arixtra in the U.S. |
Adolor is hiring a 30-person sales force and will receive undisclosed cost reimbursement for its promotional efforts (1/3) |
Anika |
Bausch & Lomb Inc. |
Multiyear supply agreement for viscoelastic products used in ophthalmic surgery |
The deal extends a long-term relationship between the companies; terms were not disclosed (12/20) |
Biosignal Ltd. |
Dr. Reddy's Laboratories (India) |
Reddy's Laboratories will develop a large-scale manufacturing procedure for Biosignal compounds |
The compounds are antibacterial furanones; terms of the deal were not disclosed (1/20) |
Cell |
Quintiles Transnational Corp. |
Six-year financing and services deal involving CTI's cancer therapy, Trisenox |
CTI gets $25M in cash and $5M in clinical services in exchange for royalties on sales in the U.S. and parts of Europe, which were projected to total at least $53M (12/21) |
Chromos |
AppTec Laboratory Services Inc. |
Alliance to provide a range of cell line engineering and contract manufacturing services |
They will coordinate marketing efforts under a nonexclusive arrangement; termswere not disclosed (2/16) |
Debiopharm |
Rowfarma S. de RL de CV (unit of Quintiles |
Rowfarma will exclusively distribute Decapeptyl in Mexico |
Debiopharm will supply the luteinizing hormone releasing hormone, and get royalties on sales (12/20) |
DOR |
Cambrex Corp. |
Deal for process development and potential large-scale production of DOR's RiVax ricin vaccine |
Cambrex will provide process development and cGMP production services for RiVax; terms were not disclosed (1/7) |
Flamel |
GlaxoSmithKline plc (UK) |
Flamel will supply GSK with commercial supplies of Flamel's Micropump formu-lation of an existing GSK drug |
GSK licensed the technology for the drug in March 2003; terms were not disclosed (12/21) |
Gen-Probe |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Gen-Probe will purchase products for use in molecular diagnostic assays for human papillomavirus |
Roche will manufacture DNA probes for HPV, which Gen-Probe will purchase at agreed-upon transfer prices (2/15) |
Helix |
American Global Health Group LLC |
Deal for inclusion of Helix peptide technology in AGHG skin care products |
The products are being developed for the Asian market; Helix is entitled to royalties on any resulting sales (2/22) |
ICOS Corp. |
Solvay Pharmaceuticals Inc. |
Co-promotion agreement for AndroGel (testosterone gel), which is approved in the U.S. |
ICOS will provide promotional support through physician details and other activities, and be paid a fee per detail, as well as fees based on specified sales goals (1/31) |
Isis |
Drug Royalty USA Inc. |
Isis sold a portion of its royalty rights in the approved ophthalmic product Macugen royalties on the first $500M of annual sales, 50% of royalties on sales between $500M |
Isis will be paid $24M over three years; through 2009, Drug Royalty gets will get and $1B, and 10% on sales in excess of $1B (12/21) |
Nymox |
Alifax SpA (Italy) |
Deal for the marketing and sales of Nymox's AlzheimAlert product in Italy |
Alifax will distribute the Alzheimer's disease diagnostic in Italy under undisclosed terms (2/16) |
Pharming |
Diosynth BV (the Netherlands; unit of Akzo Nobel) |
Supply agreement for the production of Pharming's recombinant human C1 inhibitor |
The product is being developed for hereditary angioedema; terms of the deal were not disclosed (2/8) |
ProMetic Life Sciences |
BioMena SA (Tunisia) |
BioMensa licensed ProMetic's Enabling Technology for use in manufacturing drugs for Middle East, North African and certain European markets |
ProMetic gets $2.5M up front and $2.5M over two years as a license fee; it also would get royalties on any sales (12/16) |
Qiagen NV |
Roche Molecular Systems |
Roche will market Qiagen's media sample preparation kits under its AmpliLute trademark |
Terms of the deal were not disclosed (2/9) |
Repligen |
GE Healthcare |
They amended 1999 supply agreement covering the manufacture of GE's recombinant Protein A |
The agreement was extended through 2010, and expanded to include an additional GE protein (2/8) |
Savient |
O.R.C.A.Pharm GmbH (Germany) |
Deal under which O.R.C.A. will market Soltamox (tamoxifen oral liquid solution) in Germany |
Savient subsidiary Rosemont Pharmaceuticals will manufacture the product and get payments based on sales (1/6) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
